Pfizer to Acquire Trillium Therapeutics for $2.26B; Completes Acquisition for $2.22B
Executive Summary
Pfizer Inc. entered into a definitive agreement to acquire fellow public firm Trillium Therapeutics Inc., a clinical stage immuno-oncology company developing innovative cancer therapies.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash for Equity
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice